adjunct-treatment | CARLAT PUBLISHING

RESEARCH UPDATE

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.

Does CBT Enhance Pharmacotherapy for Addiction?

July 3, 2021

Jedidiah Perdue, MD, MPH

Jedidiah Perdue, MD, MPH Dr. Perdue has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychotherapy has had a mixed track record of efficacy for substance use disorders. This meta-analysis suggests that CBT is only modestly effective when combined with medications and likely no better than any other form of therapy. Although it’s unlikely be a magic bullet, CBT is very low risk, and reasonable to offer alongside other more established treatments.

Finally, Effective Treatments for Tardive Dyskinesia

May 21, 2021

Farah Khorassani, PharmD.

Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

VMAT-2 inhibitors significantly reduce the symptoms of tardive dyskinesia. We learn how to prescribe them and what side effects and drug interactions to watch for.

Combination Treatment for Schizophrenia

April 12, 2021

T. Scott Stroup, MD, MPH

T. Scott Stroup, MD, MPH
Professor of Psychiatry, Columbia University, NY. Dr. Stroup has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. T. Scott Stroup, Professor of Psychiatry at Columbia University, reveals surprising findings from his research on the use of adjunctive medications for schizophrenia.